To the Editor: Crimean-Congo hemorrhagic fever (CCHF) is an acute viral infection that causes mild to severe hemorrhagic fever characterized by petechiae, ecchymosis, disseminated intravascular coagulation, and multi-organ failure (1). The etiologic agent, CCHF virus (CCHFV; family Bunyaviridae, genus Nairovirus), is maintained in enzootic cycles involving agricultural and wild animals and the vector, *Hyalomma* ticks. (2). CCHF predominantly affects persons who have 1) substantial contact with ticks and/or agricultural animals in areas where CCHF is endemic or 2) close contact with infected persons, predominantly close relatives and health care workers. The case-fatality rate for CCHF is generally accepted as 30% (1).

CCHF has a wide geographic distribution; cases have been reported in >30 countries across Africa, southeastern Europe, the Middle East, and western Asia. In the western African countries of Nigeria, Mauritania, and Senegal, serologic evidence of CCHFV infections in humans and agricultural animals has been documented frequently (3–5); however, reports of the disease in humans have been limited to Senegal and Mauritania (6,7). In neighboring Mali, where the tick vector is known to be present, little information exists regarding the presence of CCHFV. Thus, to determine if the virus is circulating undetected in Mali, we conducted a study to determine if CCHFV is present in *Hyalomma* ticks in the country.

In November 2011 and March 2012, unfed *Hyalomma* ticks (adults and nymphs) were collected from 20 cattle at the Daral livestock market (12° 49.855’ N, 08° 05.651’ W) near the town of Kati, Mali, ≈25 km from the capital, Bamako. In the field, ticks were visually identified to genus and pooled accordingly (3–4 ticks per pool, all collected from the same animal). A total of 23 tick pools, representing 80 ticks, were manually homogenized, and RNA was extracted and tested for the presence of CCHFV RNA by using in-house assays that selected for 3 virus genes. Of the 23 tick pools tested, 1 was positive for CCHFV by all 3 assays. Phylogenetic analysis of the complete nucleocapsid protein gene (KF793333) showed that the CCHFV strain from Mali most closely resembled a strain from Mauritania (GenBank accession no. ArD39554), sharing 98% sequence identity (Figure, panel A).

Further analysis of fragments of the medium segment (pre-Gn coding region, KF793334) and large segment (polymerase coding region, KF793335) confirmed these findings, showing sequence identities of 91% and 98%, respectively, with ArD39554 (Figure, panels B, C). In a Biosafety Level 4 facility at Rocky Mountain Laboratories, Hamilton, Montana, USA, the original homogenates from the positive pool were passaged in multiple cell lines. After 3 passages, no discernible cytopathic effect was observed and, aside from the initial passage, CCHFV RNA was not detected. Genetic identification of ticks in the CCHFV RNA–positive pool was conducted as described (8,9). Amplified sequences most closely resembled those of *H. dromedarii* (97.2%–100% sequence identity), although genetically, we cannot exclude the possibility that *H. truncatum* and *H. rufipes* were present with individual sequence identities of >97% to published sequences.

The Daral cattle market in Kati is the largest of its kind in Mali, and animals from across the country come into the market every week. Although the market provided a convenient opportunity for collecting ticks, we cannot determine where the infected
ticks, and possibly cattle, contracted CCHFV because the animals traversed great distances on foot before arriving at the market. Nevertheless, this study demonstrates the presence of a distinct strain of CCHFV in *Hyalomma* ticks in Mali, thereby expanding the geographic distribution of this virus in western Africa. Not surprisingly, the highest sequence identity for the CCHFV strain from Mali is to strains known to circulate in neighboring countries (10). We propose Daral 2012 Mali as the temporary designation for this sequence. Unfortunately, our attempts to isolate the virus were unsuccessful, most likely because of processing and storage conditions for homogenates used in these studies.

Species of *Hyalomma* ticks are widely distributed across western Africa, and although reports of CCHF are limited to a few countries, CCHFV is most likely circulating undetected in vast areas of this region. No cases of CCHF have been reported in Mali; however, on the basis of our findings, the potential for human infections exists. Thus, CCHF should be considered in the differential diagnosis of febrile illnesses, with or without hemorrhagic symptoms, in residents of Mali and for persons with a recent history of travel to this country.

The ease of CCHFV transmission and the high case-fatality rate associated with infection could have a potentially substantial effect on public health. Future studies in Mali are required to define the geographic distribution of infected ticks and animals and to isolate CCHFV to help focus public health preparedness and countermeasures. In addition, across Mali, operational protocols should be reviewed for persons working at jobs in which the risk for CCHFV transmission is high (e.g., occupations with direct contact with agricultural animals and/or animal blood products), and appropriate countermeasures should be put in place to prevent transmission among such persons.
Acknowledgments

We are indebted to the chief of Daral for allowing us access to the Kati cattle market and to the individual ranchers for providing ticks from their cattle. In addition, we thank Seydou Doumbia, Sekou Traore, Richard Sakai, Joseph Shott, and Mark Pineda for logistics support; Robert J. Fischer, Brandi Williamson, Eric Dahlstrom, and Stephen Porcella for technical assistance; and Heather Murphy for help preparing the figures.

This work was funded by the International Centers for Excellence in Research program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Marko Zivcec,
Ousmane Maïga, Ashley Kelly,
Friederike Feldmann,
Nafomon Sogoba,
Tom G. Schwan,
Heinz Feldmann,
and David Safronetz


DOI: http://dx.doi.org/10.3201/eid2005.131641

References


Coxsackievirus A16 Encephalitis during Obinutuzumab Therapy, Belgium, 2013

To the Editor: Enterovirus infections are associated with many clinical manifestations, and specific virus groups or serotypes are associated with specific manifestations. Coxsackievirus A16, a common cause of hand, foot and mouth disease, rarely causes encephalitis. Although most enterovirus infections are cleared by cellular immune responses, invasive enterovirus disease is prevented or controlled by neutralizing antibodies (1). Thus, patients with humoral immunodeficiencies are susceptible to serious enterovirus infections.

Nine cases of enteroviral encephalitis (1 caused by echovirus 13, 1 caused by coxsackievirus A16, 2 caused by enterovirus 71, and 5 caused by unknown enteroviruses) have been reported after therapy with rituximab, a monoclonal antibody (MAb) that causes secondary hypogammaglobulinemia (2). We describe coxsackievirus A16 encephalitis in a patient who was receiving treatment with the MAb obinutuzumab.

A 67-year-old woman with non-Hodgkin lymphoma showed complete remission after 6 cycles of treatment with bendamustine and obinutuzumab. Induction immunochemotherapy was followed by obinutuzumab maintenance therapy. At admission, she had received 7 of 12 scheduled treatments.

The patient was hospitalized because of a history of high-grade fever that did not respond to antimicrobial drugs, confusion, general weakness, and urinary incontinence. She had a neutrophil count of 3.1 × 10⁹ cells/L but had severe lymphocytopenia (0.3 × 10⁹ cells/L and an absolute CD4 cell count of 0.082 × 10⁹ cells/L) and low

Letters Letters commenting on recent articles as well as letters reporting cases, outbreaks, or original research are welcome. Letters commenting on articles should contain no more than 800 words and 10 references; they are more appropriate to the original article’s publication. Letters reporting cases, outbreaks, or original research should contain no more than 800 words and 10 references. They may have 1 Figure or Table and should not be divided into sections. All letters should contain material not previously published and include a word count.